Most documented pregnancies during isotretinoin treatment happen when recommended pregnancy‑prevention rules are not fully followed, and many of those cases involve using only a single (often user‑dependent) contraceptive method instead of two. Current safety programs stress that people who can become pregnant should use two effective forms of contraception together or remain strictly abstinent before, during, and after isotretinoin therapy because of the drug’s strong teratogenic risk.

Why this headline matters

Isotretinoin is a powerful acne medication but is strongly linked to severe birth defects if taken during pregnancy, so pregnancy prevention is central to safe use. Real‑world studies over the past two decades show that, despite warnings, a notable share of patients either use no contraception or rely on only one method while on isotretinoin.

What the evidence shows

  • Regulatory programs (such as iPLEDGE in the US and similar efforts in Canada and Europe) were built around the principle of two simultaneous contraceptive methods or complete abstinence to reduce fetal exposure.
  • Observational research reports that:
    • 7%–59% of women on isotretinoin use no contraception at all, and up to about 80% do not use two methods in parallel, which leaves room for method failure and “real‑world” misuse.
* Long‑acting reversible methods (like IUDs and implants) alone have very low failure rates (>99.5% effectiveness) and outperform many combinations that rely heavily on user behavior, such as pills plus condoms.

Two methods vs. one method

Many pregnancy cases during isotretinoin therapy involve:

  • Use of only one, user‑dependent method (for example, pills taken imperfectly, or condoms alone).
  • Inconsistent or incorrect use (missed pills, condoms not used every time, or interruptions in contraception around starting or stopping isotretinoin).

Because of this, guidelines emphasize:

  • At least one highly effective, low‑maintenance method (e.g., IUD, implant, or injectable progestogen) during isotretinoin.
  • Adding a barrier method (condom) when the primary method is more user‑dependent, such as combined oral contraceptives.

Current program recommendations

Modern patient guides and regulatory materials for isotretinoin usually require that patients who can get pregnant:

  • Use two effective forms of birth control together:
    • For at least 1 month before starting isotretinoin
    • Throughout the 4–5 months of typical treatment
    • For 1 month after the last dose
  • Undergo regular pregnancy testing before, during, and after therapy.

These steps aim to close the gap between ideal contraceptive effectiveness and what happens in daily life, where single‑method use and lapses in adherence have been clearly linked to the pregnancies that still occur on isotretinoin.

Information gathered from public forums or data available on the internet and portrayed here.